Heidi Overton’s FDA Bid Is Pulled After Senate Support Falters

Heidi Overton
The White House has withdrawn Dr. Heidi Overton’s nomination to lead the Food and Drug Administration, saying the decision came as signs grew that she lacked enough support in the Senate. The move ends a closely watched effort to put the physician and White House domestic policy adviser in charge of the agency. Overton has spent much of her career working for President Donald Trump or conservative organizations aligned with his agenda. Her nomination, announced in August, was presented as a bid to bring steadier leadership to the FDA after a turbulent year under the administration’s first commissioner, Dr. Marty Makary. But senators from both parties raised questions about whether Overton would act independently of Trump, particularly on vaccines. At her September confirmation hearing, Republican Sen. Bill Cassidy pressed her on the administration’s proposal to separate combination vaccines, including the measles, mumps and rubella shot. Cassidy had previously described her support for that plan as “almost disqualifying.” Cassidy, a Louisiana physician who chairs the Senate health committee, said earlier Tuesday that he remained undecided ahead of a scheduled committee vote. Later that night, he indicated he had been prepared to support Overton and suggested that disagreements over abortion, rather than vaccines, helped derail the nomination. The withdrawal came before the committee was due to consider her appointment Wednesday morning. The account does not describe Overton’s next steps, but it leaves the FDA leadership post without her as its prospective nominee.
Source ↗